Health
ATPCI: Trimetazidine Fizzles for Post-PCI Angina – Medscape
The antianginal was unable to provide added benefit when added to optimal medical therapy, but one expert questions: Was the right population studied?
Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a nonST-elevated myocardial infarction (MI), results of the ATPCI trial show.
There was no benefit for the composite primary endpoint of cardiac death, hospitalization for cardiac events, or recurrent/persistent angina requiring an addition, switch, or increased dose of antianginal therapies, or requiring coronary angiography (hazard ratio…
-
Noosa News7 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News8 hours agoMotorcyclist dies in crash with truck
-
Noosa News23 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General22 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate